The many faces of FcγRI: implications for therapeutic antibody function
- PMID: 26497519
- DOI: 10.1111/imr.12334
The many faces of FcγRI: implications for therapeutic antibody function
Abstract
Fcγ receptor I (FcγRI or CD64) is the sole human Fc receptor with high affinity for monovalent IgG. While it contains an immunoreceptor tyrosine-based activation motif in its cytoplasmic domain, binding of FcγRI can result in a complex array of activating and inhibitory outcomes. For instance, binding of monomeric IgG provides a low-intensity tonic signal through FcγRI that is necessary for full interferon γ receptor signaling in the same cell. Interaction of FcγRI with larger high-avidity complexes can result in phagocytosis, the generation of reactive oxygen species, as well as the synthesis and release of inflammatory cytokines. However, numerous reports also document potent anti-inflammatory effects brought about by FcγRI engagement with immune complexes such as the inhibition of IFNγ and TLR4 signaling, and secretion of interleukin-10. This has led to conflicting hypotheses regarding the function of FcγRI, especially with regard to its role in the efficacy of several therapeutic monoclonal antibodies. While many of these issues are still unclear, continued characterization of the regulation and context dependence of FcγRI function, as well as the molecular mechanisms responsible for these various outcomes, will improve our understanding of FcγRI biology as well as the therapeutic strategies designed to harness or constrain its actions.
Keywords: FcγRI; immune complexes; therapeutic antibodies.
Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
Similar articles
-
Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.Immunol Rev. 2015 Nov;268(1):192-200. doi: 10.1111/imr.12346. Immunol Rev. 2015. PMID: 26497521 Review.
-
High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor.Protein Eng. 1998 Mar;11(3):225-32. doi: 10.1093/protein/11.3.225. Protein Eng. 1998. PMID: 9613847
-
The high-affinity receptor for IgG, FcγRI, of humans and non-human primates.Immunol Rev. 2015 Nov;268(1):175-91. doi: 10.1111/imr.12366. Immunol Rev. 2015. PMID: 26497520 Review.
-
Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.Sci Signal. 2018 Jul 24;11(540):eaaq0891. doi: 10.1126/scisignal.aaq0891. Sci Signal. 2018. PMID: 30042128 Free PMC article.
-
Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions.J Immunol. 2017 Oct 1;199(7):2432-2439. doi: 10.4049/jimmunol.1601929. Epub 2017 Aug 16. J Immunol. 2017. PMID: 28814603
Cited by
-
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors.Antibodies (Basel). 2021 Nov 4;10(4):44. doi: 10.3390/antib10040044. Antibodies (Basel). 2021. PMID: 34842612 Free PMC article. Review.
-
Modulation of Microglial Cell Fcγ Receptor Expression Following Viral Brain Infection.Sci Rep. 2017 Feb 6;7:41889. doi: 10.1038/srep41889. Sci Rep. 2017. PMID: 28165503 Free PMC article.
-
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.Oncotarget. 2017 Jun 6;8(23):37128-37139. doi: 10.18632/oncotarget.16201. Oncotarget. 2017. PMID: 28415754 Free PMC article.
-
Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations.Annu Rev Biomed Eng. 2022 Jun 6;24:249-274. doi: 10.1146/annurev-bioeng-082721-024500. Epub 2022 Apr 1. Annu Rev Biomed Eng. 2022. PMID: 35363537 Free PMC article. Review.
-
Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.Biochim Biophys Acta Gen Subj. 2023 Nov;1867(11):130448. doi: 10.1016/j.bbagen.2023.130448. Epub 2023 Aug 29. Biochim Biophys Acta Gen Subj. 2023. PMID: 37652365 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
